Semaglutide Use Has Prompted 'Staggering' Number Of GLP-1 Poison Control Calls

Semaglutide Use Has Prompted 'Staggering' Number Of GLP-1 Poison Control Calls According to a study, call volumes nearly doubled after the 2021 approval of semaglutide for the treatment of obesity, rising from roughly 1,000 to 1,500 cases annually to over 8,000 by 2023, HealthDay News reports. https://kffhealthnews.org/morning-breakout/pharmaceuticals-062626/